222 related articles for article (PubMed ID: 33986121)
1. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.
Alzofon N; Koc K; Panwell K; Pozdeyev N; Marshall CB; Albuja-Cruz M; Raeburn CD; Nathanson KL; Cohen DL; Wierman ME; Kiseljak-Vassiliades K; Fishbein L
Mol Cancer Res; 2021 Sep; 19(9):1476-1485. PubMed ID: 33986121
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
3. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
Ghosal S; Das S; Pang Y; Gonzales MK; Huynh TT; Yang Y; Taieb D; Crona J; Shankavaram UT; Pacak K
Int J Cancer; 2020 Apr; 146(8):2326-2335. PubMed ID: 31469413
[TBL] [Abstract][Full Text] [Related]
4. Rethinking pheochromocytomas and paragangliomas from a genomic perspective.
Castro-Vega LJ; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Favier J
Oncogene; 2016 Mar; 35(9):1080-9. PubMed ID: 26028031
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.
Fishbein L; Leshchiner I; Walter V; Danilova L; Robertson AG; Johnson AR; Lichtenberg TM; Murray BA; Ghayee HK; Else T; Ling S; Jefferys SR; de Cubas AA; Wenz B; Korpershoek E; Amelio AL; Makowski L; Rathmell WK; Gimenez-Roqueplo AP; Giordano TJ; Asa SL; Tischler AS; ; Pacak K; Nathanson KL; Wilkerson MD
Cancer Cell; 2017 Feb; 31(2):181-193. PubMed ID: 28162975
[TBL] [Abstract][Full Text] [Related]
8. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors.
Jochmanová I; Zelinka T; Widimský J; Pacak K
Physiol Res; 2014; 63(Suppl 2):S251-62. PubMed ID: 24908231
[TBL] [Abstract][Full Text] [Related]
9. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
10. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
Smestad JA; Maher LJ
BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
[TBL] [Abstract][Full Text] [Related]
11. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
12. Genetics of pheochromocytoma and paraganglioma.
Wachtel H; Fishbein L
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):283-290. PubMed ID: 33764930
[TBL] [Abstract][Full Text] [Related]
13. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract][Full Text] [Related]
14. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
16. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
Tevosian SG; Ghayee HK
J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
[TBL] [Abstract][Full Text] [Related]
18. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
19. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
